-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

Benzinga·10/06/2026 12:14:13
Listen to the news
Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $80.